Innovus Pharmaceuticals, Inc.
30 articles with Innovus Pharmaceuticals, Inc.
-
Innovus Pharma’s Product FlutiCare® Ranks #2 Behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray Categories
2/1/2019
Company Places Additional Order of 220,000 Units to Meet Growing Demand
-
Innovus Pharma Announces the Approval and Launch of its OTC Hemorrhoid Xyralid® Suppositories in Canada
1/31/2019
Xyralid®, Suppositories for the Reduction of Swelling and Inflammation of Hemorrhoidal Tissues, is the Ninth Innovus Pharma Product launched in Canada to Date
-
Innovus Pharmaceuticals Announces $3.17 Million Private Placement
12/31/2018
Innovus Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with a healthcare-dedicated institutional investor for the sale of 45,306,347 shares of common stock (or common stock equivalents), series A warrants to purchase up to 45,306,347 shares of common stock and series B warrants to purchase up to 45,306,347 shares of common stock in a private placement at a price of $0.07 per share and associated warrants for gross proceeds of approximately $3.17 million.
-
Innovus Pharma Announces All Cash Acquisition of All of the Assets of SupplementHunt.com, an E-Commerce Store with its Proprietary Sales Platform and Marketing Technology
12/14/2018
Acquisition Currently Expected to Add $2 million in Revenue to Innovus Pharma on a Yearly Basis
-
Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin™ on Muscle Health in Adults in the United States
12/10/2018
Clinical Study will be Completed and its Results Announced in the First Half of 2019
-
Innovus Pharmaceuticals Acquires Worldwide Rights to Four Products from Boston Topicals, LLC
11/19/2018
HealthiFeet®, Among the Products Acquired, Has Been a Proven Category Leader in Pilot Programs in Multiple Retail Stores
-
Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately $7.4 Million for the Third Quarter 2018 and $19.2 Million for the First Nine Months of 2018
11/14/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, announced today its reported results for the third quarter 2018.
-
Innovus Pharmaceuticals to Release Its Third Quarter 2018 Financial Results on Wednesday, November 14, 2018
11/8/2018
Innovus Pharmaceuticals, Inc., today announced that the Company will release its third quarter financial results on Wednesday, November 14, 2018.
-
Innovus Pharmaceuticals Reports Preliminary Q3 2018 Sales Revenue of $7.0 million to $7.1 million
11/5/2018
Preliminary Quarterly Revenue Increase of 215-219% Comparable to 2017 Third Quarter
-
Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip Products
10/23/2018
Innovus Pharmaceuticals, Inc. announced today that its GlucoGorx™ Blood Glucose Monitoring System and GlucoGorx™ Blood Glucose Test Strip products have become eligible for Medicare reimbursement.
-
Innovus Pharma Announces Planned Expansion into CBD Oil-Based Products Market
10/18/2018
First Product MZS Sleeping Aid™ Currently Expected to Launch in the U.S. in Q4 2018
-
Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference
8/29/2018
Innovus Pharmaceuticals, Inc. today announced that Dr. Bassam Damaj, President & Chief Executive Officer, and Ryan Selhorn, Vice President, Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th Annual Global Investment Conference
-
Innovus Pharma Signs Purchase Agreement with “Showcase – The Home of the Hottest Trends” to Sell the Company’s Apeaz® Cream for the Relief of Arthritis Pain in Its 110 “Showcase” Retail Stores in the United States and Canada
8/10/2018
Apeaz® is the Fifth Company Product to Be Sold in Retails Stores in the U.S. and Canada
-
Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid® Suppositories, Beyond Human® Testosterone and RecalMax™
8/7/2018
The Three Potential Products, If Approved, Will Supplement the Company’s Eight Products Launched in Canada to Date
-
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
8/3/2018
Innovus Pharmaceuticals, Inc. announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets.
-
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
7/19/2018
CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products
-
Innovus Pharmaceuticals Reports Preliminary Q2 2018 Sales Revenue of $6.6 million to $6.8 million
7/17/2018
Preliminary Quarterly Revenue Increase of 47-51% and Comparable 2017 Second Quarter Increase of 330-340% and Fiscal Year 2018 Net Revenue Annual Guidance Adjusted Upwards to at Least $22 Million
-
Innovus Pharmaceuticals, Inc.: Strong Growth in the OTC Personal Care Market -- SECFilings.com
6/22/2018
SECFilings.com announces the publication of an article covering Innovus Pharmaceuticals Inc.
-
Innovus Pharma Announces the Launch of Its Product AllerVarx™ in Canada for Allergic Rhinitis
6/6/2018
AllerVarx™ is the Ninth Innovus Pharma Product Launched in Canada to Date
-
Innovus Pharma Announces the Approval of Its Product ProstaGorx™ in Canada for Benign Prostatic Hyperplasia (“BPH”)
6/4/2018
Innovus Pharmaceuticals, Inc. announced the approval by Health Canada of its product ProstaGorx™ as a Natural Health Product (NPN #80085717) for the relief of urologic symptoms.